RE:RE:MacimorelinAlex1726 wrote:
Macimorelin could be a very valuable asset , maybe more than PGX. Make your own opinion and share it.
https://www.evaluate.com/vantage/articles/news/deals/flipping-win-strongbridge-biopharma
Based on PGX CoQ10 results published in Oct., 2023 I would say that PGX could easily attract a partner to fund the next commercial stage, so it definitely has more potential esp. given that PGX is a delivery system for bioactives with endless possibilities.
https://stockhouse.com/news/press-releases/2022/10/13/ceapro-inc-announces-positive-data-from-bioavailability-studies-evaluating-coq10 We just need a CEO who cares about shareholders who can make a commerical deal, and BTW, a PGX CoQ10 deal was a target for H2 2023. That was likely put on the backburner as priority was given to the self serving desire to have AEZS take over CZO's dirsuptive PGX tech so it could be used as a lifeline so AEZS could tout it to raise funds.